What the label lists and what reports show
Glipizide side effects
Glipizide's FDA label: “Most common adverse reactions (incidence > 3%) are dizziness, diarrhea, nervousness, tremor, hypoglycemia and flatulence ( 6.1 ).” FAERS holds 60,555 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is blood glucose increased (6,708 reports).
- Generic listed
Check it at the source: the glipizide FDA label on DailyMed (effective January 8, 2026, Aurobindo Pharma Limited); the FDA FAERS public dashboard.
What does the patient leaflet say about side effects?
From the patient leaflet: What are the possible side effects of glipizide extended-release tablets?Glipizide extended-release tablets can cause serious side effects, including: Low blood sugar. Glipizide extended-release tablets may cause low blood sugar. Signs and symptoms of low blood sugar may include: ● a cold clammy feeling ● hunger ● unusual sweating ● fast heartbeat ● dizziness ● headache ● weakness ● blurred vision ● trembling ● slurred speech ● shakiness ● tingling in the lips or hands If you have signs or symptoms of low blood sugar, eat or drink something with sugar in it right away. If you do not feel better or your blood sugar level does not go up, call your healthcare provider or go to the nearest emergency room. The most common side effects of glipizide extended-release tablets include: dizziness, diarrhea, nervousness, tremor, and gas. These are not all the possible side effects of glipizide extended-release tablets. […]
Source: FDA drug label, Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
What does the label list?
From the label: adverse reactionsMost common adverse reactions (incidence > 3%) are dizziness, diarrhea, nervousness, tremor, hypoglycemia and flatulence ( 6.1 ).
Table 1: Incidence (%) of Adverse Reactions Reported in ≥3% of Patients Treated in…
| Reaction | Glipizide extended-release tablets (%) (N=278) | Placebo (%) (N=69) |
|---|---|---|
| Adverse Effect Dizziness | 6.8 | 5.8 |
| Diarrhea | 5.4 | 0.0 |
| Nervousness | 3.6 | 2.9 |
| Tremor | 3.6 | 0.0 |
| Flatulence | 3.2 | 1.4 |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
From the label: adverse reactions, continuedThe followingserious adverse reactions are discussedinmoredetail below and elsewhereinthe labeling: Hypoglycemia [see Warnings and Precautions (5.1) ] Hemolyticanemia [see Warnings and Precautions (5.2) ] Most common adverse reactions (incidence > 3%) are dizziness, diarrhea, nervousness, tremor, hypoglycemia and flatulence ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials, 580 patients from 31 to 87 years of age received glipizide extended-release tablets in doses from 5 mg to 60 mg in both controlled and open trials. The dosages above 20 mg are not recommended dosages. In these trials, approximately 180 patients were treated with glipizide extended-release tablets for at least 6 months. Table 1 summarizes the incidence of adverse reactions, other than hypoglycemia, that were reported in pooled double-blind, placebo-controlled trials in ≥3% of glipizide extended-release tablets-treated patients and more commonly than in patients who received placebo.
Source: FDA drug label, Aurobindo Pharma Limited, effective January 8, 2026 (SPL set 84794a52-b717-488c-8533-6425c83d405f), via openFDA; the full label on DailyMed
What do FAERS reports show?
60,555 reports list glipizide among the medicines taken, each a report of something that happened, not proof the medicine caused it; 5,339 are coded as a death and 18,120 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 22 reactions below, 6 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Glipizide: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions